Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.60 |
| ▸ | METAP1 | P53582 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7518685 | 0.81 | CYP19A1 (0.49) | ACHETSHRMAPTALDH1A1HPGD | |
| SCHEMBL2909996 | 0.77 | METAP1 (0.56) | ACHEMETAP1 | |
| SCHEMBL22744723 | 0.76 | ACHE (0.50) | ACHEMETAP1TSHRMAPTALDH1A1 | |
| SCHEMBL354925 | 0.75 | ACHE (1.00) | ACHEMETAP1TSHRCYP19A1 | |
| SCHEMBL13866434 | 0.75 | ACHE (1.00) | ACHEMETAP1TSHRCYP19A1 | |
| SCHEMBL4938272 | 0.75 | ACHE (1.00) | ACHEMETAP1TSHRCYP19A1 | |
| SCHEMBL9752693 | 0.75 | ACHE (1.00) | ACHEMETAP1TSHRCYP19A1 | |
| SCHEMBL14534943 | 0.74 | ACHE (0.49) | ACHEMETAP1TSHRMAPTALDH1A1 | |
| SCHEMBL14157895 | 0.74 | ACHE (0.63) | ACHEMETAP1TSHRMAPTCYP19A1 | |
| SCHEMBL5539639 | 0.74 | ACHE (0.63) | ACHEMETAP1TSHRMAPTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111225875-B | Salt recovery solution and method of using salt recovery solution | 阿克福特斯技术有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-113891760-A | Solvent drying compositions and related methods | 阿克福特斯技术有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-111225875-A | Salt recovery solution and method of using salt recovery solution | 阿克福特斯技术有限公司 | 2020-06-02 | — | — | CN | disclosed |
| US-6638685-B2 | Resolution, sensitivity and smoothness on side surfaces of a transferred pattern; photolithography | NEC CORPORATION (JP) | 2003-10-28 | — | — | US | disclosed |
| US-6528232-B1 | Chemically amplified photoresist composition using the novel sulfonium salt compound as the photoacid generator | NEC CORPORATION (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20020182535-A1 | Photoacid generator containing two kinds of sulfonium salt compound, chemically amplified resist containing the same and pattern transfer method | NEC CORPORATION (JP) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020182535-A1 | Photoacid generator containing two kinds of sulfonium salt compound, chemically amplified resist containing the same and pattern transfer method | ASIC1, ASIC3, SULT1A1 | ACHE 4771/4885METAP1 3725/4885TSHR 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.